{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-014494","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2022-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.734331+00:00","generated_at":"2026-06-26T07:24:39.068184+00:00","sec_items":["2.0","5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Imara cuts 83% of workforce, ends all pipeline programs, reviews strategic options","bullets":["Workforce reduction of ~83% leaves only 6 full-time employees; substantially complete by Q2 2022.","Discontinues tovinontrine (IMR-687) in sickle cell, beta-thalassemia, and heart failure with preserved ejection fraction.","Also discontinues development of IMR-261; company starts comprehensive strategic review to maximize shareholder value.","One-time restructuring charge of $2.0-2.2 million expected in Q2 2022 for severance and benefits.","Chief Medical Officer Kenneth Attie, M.D. departs effective April 20, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-014494","json":"https://secwatch.observer/filing/0001564590-22-014494.json","markdown":"https://secwatch.observer/filing/0001564590-22-014494.md","text":"https://secwatch.observer/filing/0001564590-22-014494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000156459022014494/0001564590-22-014494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000156459022014494/imra-8k_20220405.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:24:39.068184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4caef0eac8","claim":"Kenneth Attie departed as Chief Medical Officer at Enliven Therapeutics, Inc..","evidence_excerpt":"Kenneth Attie, M.D., the Company’s Chief Medical Officer will separate from the Company effective April 20, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000156459022014494/0001564590-22-014494-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}